Biopharma AI
ByCan Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
Can Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Strategic Industry Release: How AI Companies Led Biopharma Innovation Through Major Collaborations in 2025
Artificial intelligence companies emerged as critical innovation partners for the global biopharmaceutical industry in 2025, reshaping how drugs…
GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record in China Rewrite the Global Timeline for Bringing New Medicines to Patients?
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s disclosure that it…
